Medical Marketing and Media |
Sanofi to stop marketing Afrezza, citing low Rx
Medical Marketing and Media Sanofi in April will stop marketing Afrezza, MannKind's inhaled insulin, citing the low number of prescriptions even though the drugmaker made what it described as a “substantial” investment in sales and marketing, including the launch of the “Surprise ... Sanofi Ends Marketing Deal With Developer of Inhaled Insulin |
January 05, 2016 at 07:37PM | marketing - Google News
Sanofi to stop marketing Afrezza, citing low Rx - Medical Marketing and Media
marketing - Google News
Nenhum comentário:
Postar um comentário